Business Context and Reporting Period
Company: Hemispherx Biopharma, Inc. (Note: Request metadata referenced "AIM Immunotech Inc.", but the filing text identifies the registrant as Hemispherx Biopharma, Inc.)
Filing Type: Form 8-K (Current Report)
Date: July 23, 2012
Event: Entry into a Material Definitive Agreement (Equity Distribution Agreement).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a financing arrangement with the following parameters:
- Maximum Offering Size: Up to $75,000,000 in common stock.
- Sales Agent: Maxim Group LLC.
- Commission Structure: 4.0% on the first $10,000,000 of gross proceeds; 3.0% on proceeds thereafter.
- Method: At-the-market offerings (Rule 415) via ordinary brokers' transactions.
Material Changes
The Company entered into an Equity Distribution Agreement on July 23, 2012, authorizing the sale of shares through an at-the-market program. This represents a new mechanism for raising capital compared to prior periods, though no specific financial performance changes are reported in this document.
Guidance, Outlook, and Risks
- Management Commentary: The Company has no obligation to sell any shares under the agreement and retains the right to suspend offers or terminate the agreement at any time.
- Regulatory Status: Shares will be issued pursuant to a previously effective Registration Statement on Form S-3 (File No. 333-182216). A Prospectus Supplement was filed on July 23, 2012.
- Risks/Contingencies: Sales are subject to market conditions and the Company's discretion. The filing explicitly states it does not constitute an offer to sell in states where such an offer would be unlawful prior to registration.
Investor Verification Checklist
- Verify the current share price and trading volume on the NYSE MKT to assess the potential dilution impact of a $75 million offering.
- Review the filed Equity Distribution Agreement (Exhibit 10.1) for specific termination clauses and conditions.
- Confirm the Company's current cash position and burn rate to understand the urgency of this capital raise.
- Check for any subsequent 8-K filings indicating the actual execution of share sales under this agreement.